Intravenous Immunoglobulin

Study: Experimental Alzheimer's drug stabilizes symptoms for up to three years

Treatment with an experimental intravenous Alzheimer's medication stabilized dementia symptoms for a sustained period in trial participants, new research reveals. Investigators called it a "first" in Alzheimer's research.